Where global mAb, ADC and next gen
technology stakeholders meet to do business


Everything biopharma needs to know to fast track vaccines, biologics and biosimilars development

US-focused mAbs market discussion
Following the success of our European Antibody Congress is the inaugural Americas Antibody Congress where biopharma gather to discuss strategies and opportunities across mAbs, ADCs, bi/multispecifics, novel formats and biosimilars.

The US is projected to be the largest single market for therapeutic mAbs from $20.1B in 2011 to to $27.4B by 2016. And although there have been a number of mAbs entering the market, high development costs and time-consuming R&D and clinical trials make it difficult to gain faster entry in the market.

Addressing high development cost and time-consuming R&D
Americas Antibody Congress 2015 will bring together mAb, ADC and next generation technology stakeholders to meet and discuss strategies to  address high development costs and time consuming R&D. Case studies, panel discussions, technical showcases, inspiring keynotes with many opportunities for networking and meetings fill the two days.






Error processing SSI file